Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $111.94 Consensus Target Price from Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $111.9444.

Several research firms have commented on ZBH. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a research report on Friday, October 10th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Evercore ISI cut their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. Raymond James Financial raised their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $101.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, October 22nd.

Zimmer Biomet Trading Down 0.7%

NYSE:ZBH opened at $99.86 on Friday. The business’s 50-day moving average is $101.30 and its two-hundred day moving average is $97.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet has a 12 month low of $89.22 and a 12 month high of $114.72. The firm has a market capitalization of $19.78 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company posted $2.01 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by corporate insiders.

Institutional Trading of Zimmer Biomet

Large investors have recently modified their holdings of the business. Cullen Frost Bankers Inc. grew its stake in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the first quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC grew its stake in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. Root Financial Partners LLC acquired a new position in Zimmer Biomet in the third quarter worth about $31,000. Finally, Accent Capital Management LLC acquired a new position in Zimmer Biomet in the first quarter worth about $35,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.